Updates on PERSIST-1 trial of pacritinib for myelofibrosis

Updates on PERSIST-1 trial of pacritinib for myelofibrosis

VJHemOnc

3 years
393 Views
Share
Want to watch this again later?
Sign in to add this video to a playlist. Login
0 0
Category:
Description:
Ruben Mesa, MD from the Mayo Clinic, Phoenix, AZ discusses updates to the Phase III PERSIST-1 trial of pacritinib for myelofibrosis presented at the American Society of Oncology (ASCO) 2016 Annual Meeting held in Chicago, IL. Pacritinib is an oral JAK2/FLT3 inhibitor and the PERSIST-1 study (NCT01773187) looks at pacritinib vs best alternative therapy in patients who are JAK inhibitor naive and could have any platelet count at trial entry. Dr Mesa talks about the long-term data, which show improvements in splenomegaly and symptoms. He further discusses the concerns around the safety of the drug, in particular the number of patients passing away during the study. According to Dr Mesa, the analysis of the data seems to suggest that this is due to adverse patient selection.
Up Next Autoplay
Long-Term Results from Phase 3 ALTA-1L Trial
Long-Term Results from Phase 3 ALTA-1L Trial
Category: Non-Small Cell Lung Cancer
5 Views
Cancer-News 9 hours
Mount Sinai Receives $1 Million Grant for Prostate Cancer Research
Mount Sinai Receives $1 Million Grant for Prostate Cancer Research
Category: News
2 Views
Cancer-News 11 hours
Treatment-Free Survival, With and Without Toxicity
Treatment-Free Survival, With and Without Toxicity
Category: Kidney Cancer
7 Views
kidneycancer 13 hours
Phase 2 Study of Lenvatinib Plus Pembrolizumab for Disease Progression After PD-1/PD-L1
Phase 2 Study of Lenvatinib Plus Pembrolizumab for Disease Progression After PD-1/PD-L1
Category: Kidney Cancer
0 Views
kidneycancer 13 hours
What's To Come in Modern Imaging Technology
What's To Come in Modern Imaging Technology
Category: Kidney Cancer
3 Views
kidneycancer 1 day
Moleculin Announces Additional Positive Interim Results from Phase 1/2 Clinical Studies of Annamycin in Acute Myeloid Leukemia
Moleculin Announces Additional Positive Interim Results from Phase 1/2 Clinical Studies of Annamycin in Acute Myeloid Leukemia
Category: Acute Myelogenous Leukemia
4 Views
Cancer-News 1 day
CytoDyn Reports Early Results from First Patient in its Phase 1b/2 CCR5+ Metastatic Triple-Negative Breast Cancer Trial
CytoDyn Reports Early Results from First Patient in its Phase 1b/2 CCR5+ Metastatic Triple-Negative Breast Cancer Trial
Category: Breast Cancer
6 Views
Cancer-News 1 day
Modern Imaging Technology
Modern Imaging Technology
Category: Kidney Cancer
7 Views
kidneycancer 2 days
ASH Releases New Clinical Practice Guidelines on Immune Thrombocytopenia
ASH Releases New Clinical Practice Guidelines on Immune Thrombocytopenia
Category: News
2 Views
Cancer-News 2 days
Management of Clinical Cases in Kidney Cancer
Management of Clinical Cases in Kidney Cancer
Category: Kidney Cancer
7 Views
kidneycancer 3 days